KRAS and cancer: By contrast, glecirasib exhibited very weak p-ERK inhibitory activity in non-KRAS p.G12C cancer cells, with a median IC50 value of 5,787 nmol/L (n = 3; Fig. 2A; Supplementary Table S7).